Related Experiment Videos
Drugs and the retina
Simon Constable1, Munir Pirmohamed
1Department of Pharmacology and Therapeutics, University of Liverpool, Ashton Street Medical School, UK.
Expert Opinion on Drug Safety
|May 25, 2004
Summary
The blood-retinal barrier protects the retina, but some drugs like Vigabatrin and Hydroxychloroquine can cause retinal toxicity. Ophthalmological monitoring is crucial for patients taking these medications.
Area of Science:
- Ophthalmology
- Pharmacology
- Toxicology
Background:
- The retina is protected by the blood-retinal barrier, maintaining its specialized environment.
- Systemic drug administration can lead to retinal toxicity despite this barrier.
- Ophthalmological screening is recommended for certain medications due to potential retinal adverse effects.
Purpose of the Study:
- To review drugs associated with retinal toxicity.
- To highlight the importance of monitoring for adverse drug reactions in the retina.
- To discuss the retina as both a site of toxicity and therapeutic action.
Main Methods:
- Literature review of drugs affecting the retina.
- Analysis of known drug-induced retinal toxicities.
- Examination of therapeutic applications targeting the retina.
Main Results:
- Vigabatrin (epilepsy treatment) is linked to visual field defects in ~40% of patients.
- Hydroxychloroquine (rheumatoid arthritis, lupus) is associated with retinopathy.
- Antiviral agents for cytomegalovirus retinitis can cause systemic toxicity.
Conclusions:
- Certain systemic drugs pose a risk of retinal toxicity, necessitating ophthalmological monitoring.
- Drug dosage may influence the likelihood of retinal adverse reactions.
- The retina is a critical site for both adverse drug events and targeted pharmacological interventions.